世界の呼吸器抗ウイルス治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Respiratory Antiviral Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4815 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、呼吸器抗ウイルス治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（インフルエンザ、細気管支炎、肺炎、上気道感染症（URTI）、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・呼吸器抗ウイルス治療の市場動向 ・企業の競争状況、市場シェア ・呼吸器抗ウイルス治療の種類別市場規模と予測2016-2027（インフルエンザ、細気管支炎、肺炎、上気道感染症（URTI）、その他） ・呼吸器抗ウイルス治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・呼吸器抗ウイルス治療の北米市場規模2016-2027（アメリカ、カナダ） ・呼吸器抗ウイルス治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・呼吸器抗ウイルス治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・呼吸器抗ウイルス治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・呼吸器抗ウイルス治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（F. Hoffmann-La Roche Ltd.、Novartis AG、Takeda Pharmaceutical Company Limited、Pfizer, Inc.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Ltd.、GlaxoSmithKline plc、Mylan Inc.、Merck & Co., Inc.、AstraZeneca plc.） ・結論

Market Analysis and Insights: Global Respiratory Antiviral Treatment Market
The global Respiratory Antiviral Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Respiratory Antiviral Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Respiratory Antiviral Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Respiratory Antiviral Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Respiratory Antiviral Treatment market.

Global Respiratory Antiviral Treatment Scope and Market Size
Respiratory Antiviral Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Respiratory Antiviral Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Influenza
Bronchiolitis
Pneumonia
Upper Respiratory Tract Infections (URTIs)
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
F. Hoffmann-La Roche Ltd.
Novartis AG
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Mylan Inc.
Merck & Co., Inc.
AstraZeneca plc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Antiviral Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Influenza
1.2.3 Bronchiolitis
1.2.4 Pneumonia
1.2.5 Upper Respiratory Tract Infections (URTIs)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Respiratory Antiviral Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Respiratory Antiviral Treatment Market Perspective (2016-2027)
2.2 Respiratory Antiviral Treatment Growth Trends by Regions
2.2.1 Respiratory Antiviral Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Respiratory Antiviral Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Respiratory Antiviral Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Respiratory Antiviral Treatment Industry Dynamic
2.3.1 Respiratory Antiviral Treatment Market Trends
2.3.2 Respiratory Antiviral Treatment Market Drivers
2.3.3 Respiratory Antiviral Treatment Market Challenges
2.3.4 Respiratory Antiviral Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Respiratory Antiviral Treatment Players by Revenue
3.1.1 Global Top Respiratory Antiviral Treatment Players by Revenue (2016-2021)
3.1.2 Global Respiratory Antiviral Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Respiratory Antiviral Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Respiratory Antiviral Treatment Revenue
3.4 Global Respiratory Antiviral Treatment Market Concentration Ratio
3.4.1 Global Respiratory Antiviral Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Antiviral Treatment Revenue in 2020
3.5 Respiratory Antiviral Treatment Key Players Head office and Area Served
3.6 Key Players Respiratory Antiviral Treatment Product Solution and Service
3.7 Date of Enter into Respiratory Antiviral Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Respiratory Antiviral Treatment Breakdown Data by Type
4.1 Global Respiratory Antiviral Treatment Historic Market Size by Type (2016-2021)
4.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2022-2027)

5 Respiratory Antiviral Treatment Breakdown Data by Application
5.1 Global Respiratory Antiviral Treatment Historic Market Size by Application (2016-2021)
5.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Respiratory Antiviral Treatment Market Size (2016-2027)
6.2 North America Respiratory Antiviral Treatment Market Size by Type
6.2.1 North America Respiratory Antiviral Treatment Market Size by Type (2016-2021)
6.2.2 North America Respiratory Antiviral Treatment Market Size by Type (2022-2027)
6.2.3 North America Respiratory Antiviral Treatment Market Size by Type (2016-2027)
6.3 North America Respiratory Antiviral Treatment Market Size by Application
6.3.1 North America Respiratory Antiviral Treatment Market Size by Application (2016-2021)
6.3.2 North America Respiratory Antiviral Treatment Market Size by Application (2022-2027)
6.3.3 North America Respiratory Antiviral Treatment Market Size by Application (2016-2027)
6.4 North America Respiratory Antiviral Treatment Market Size by Country
6.4.1 North America Respiratory Antiviral Treatment Market Size by Country (2016-2021)
6.4.2 North America Respiratory Antiviral Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Respiratory Antiviral Treatment Market Size (2016-2027)
7.2 Europe Respiratory Antiviral Treatment Market Size by Type
7.2.1 Europe Respiratory Antiviral Treatment Market Size by Type (2016-2021)
7.2.2 Europe Respiratory Antiviral Treatment Market Size by Type (2022-2027)
7.2.3 Europe Respiratory Antiviral Treatment Market Size by Type (2016-2027)
7.3 Europe Respiratory Antiviral Treatment Market Size by Application
7.3.1 Europe Respiratory Antiviral Treatment Market Size by Application (2016-2021)
7.3.2 Europe Respiratory Antiviral Treatment Market Size by Application (2022-2027)
7.3.3 Europe Respiratory Antiviral Treatment Market Size by Application (2016-2027)
7.4 Europe Respiratory Antiviral Treatment Market Size by Country
7.4.1 Europe Respiratory Antiviral Treatment Market Size by Country (2016-2021)
7.4.2 Europe Respiratory Antiviral Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antiviral Treatment Market Size (2016-2027)
8.2 Asia-Pacific Respiratory Antiviral Treatment Market Size by Type
8.2.1 Asia-Pacific Respiratory Antiviral Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Respiratory Antiviral Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Respiratory Antiviral Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Respiratory Antiviral Treatment Market Size by Application
8.3.1 Asia-Pacific Respiratory Antiviral Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Respiratory Antiviral Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Respiratory Antiviral Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region
8.4.1 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Respiratory Antiviral Treatment Market Size (2016-2027)
9.2 Latin America Respiratory Antiviral Treatment Market Size by Type
9.2.1 Latin America Respiratory Antiviral Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Respiratory Antiviral Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Respiratory Antiviral Treatment Market Size by Type (2016-2027)
9.3 Latin America Respiratory Antiviral Treatment Market Size by Application
9.3.1 Latin America Respiratory Antiviral Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Respiratory Antiviral Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Respiratory Antiviral Treatment Market Size by Application (2016-2027)
9.4 Latin America Respiratory Antiviral Treatment Market Size by Country
9.4.1 Latin America Respiratory Antiviral Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Respiratory Antiviral Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antiviral Treatment Market Size (2016-2027)
10.2 Middle East & Africa Respiratory Antiviral Treatment Market Size by Type
10.2.1 Middle East & Africa Respiratory Antiviral Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Respiratory Antiviral Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Respiratory Antiviral Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Respiratory Antiviral Treatment Market Size by Application
10.3.1 Middle East & Africa Respiratory Antiviral Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Respiratory Antiviral Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Respiratory Antiviral Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country
10.4.1 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Details
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Respiratory Antiviral Treatment Introduction
11.2.4 Novartis AG Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.2.5 Novartis AG Recent Development
11.3 Takeda Pharmaceutical Company Limited
11.3.1 Takeda Pharmaceutical Company Limited Company Details
11.3.2 Takeda Pharmaceutical Company Limited Business Overview
11.3.3 Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Introduction
11.3.4 Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.3.5 Takeda Pharmaceutical Company Limited Recent Development
11.4 Pfizer, Inc.
11.4.1 Pfizer, Inc. Company Details
11.4.2 Pfizer, Inc. Business Overview
11.4.3 Pfizer, Inc. Respiratory Antiviral Treatment Introduction
11.4.4 Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.4.5 Pfizer, Inc. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Company Details
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.6.4 Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Development
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Details
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Respiratory Antiviral Treatment Introduction
11.7.4 GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.7.5 GlaxoSmithKline plc Recent Development
11.8 Mylan Inc.
11.8.1 Mylan Inc. Company Details
11.8.2 Mylan Inc. Business Overview
11.8.3 Mylan Inc. Respiratory Antiviral Treatment Introduction
11.8.4 Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.8.5 Mylan Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Respiratory Antiviral Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.9.5 Merck & Co., Inc. Recent Development
11.10 AstraZeneca plc.
11.10.1 AstraZeneca plc. Company Details
11.10.2 AstraZeneca plc. Business Overview
11.10.3 AstraZeneca plc. Respiratory Antiviral Treatment Introduction
11.10.4 AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2016-2021)
11.10.5 AstraZeneca plc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Respiratory Antiviral Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Influenza
Table 3. Key Players of Bronchiolitis
Table 4. Key Players of Pneumonia
Table 5. Key Players of Upper Respiratory Tract Infections (URTIs)
Table 6. Key Players of Others
Table 7. Global Respiratory Antiviral Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Respiratory Antiviral Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Respiratory Antiviral Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Respiratory Antiviral Treatment Market Share by Regions (2016-2021)
Table 11. Global Respiratory Antiviral Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Respiratory Antiviral Treatment Market Share by Regions (2022-2027)
Table 13. Respiratory Antiviral Treatment Market Trends
Table 14. Respiratory Antiviral Treatment Market Drivers
Table 15. Respiratory Antiviral Treatment Market Challenges
Table 16. Respiratory Antiviral Treatment Market Restraints
Table 17. Global Respiratory Antiviral Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Respiratory Antiviral Treatment Market Share by Players (2016-2021)
Table 19. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Respiratory Antiviral Treatment as of 2020)
Table 20. Ranking of Global Top Respiratory Antiviral Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Respiratory Antiviral Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Respiratory Antiviral Treatment Product Solution and Service
Table 24. Date of Enter into Respiratory Antiviral Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Respiratory Antiviral Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Respiratory Antiviral Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Respiratory Antiviral Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Respiratory Antiviral Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Respiratory Antiviral Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Respiratory Antiviral Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Respiratory Antiviral Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Respiratory Antiviral Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Respiratory Antiviral Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Respiratory Antiviral Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Respiratory Antiviral Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Respiratory Antiviral Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Respiratory Antiviral Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Respiratory Antiviral Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Respiratory Antiviral Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Respiratory Antiviral Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Respiratory Antiviral Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Respiratory Antiviral Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Respiratory Antiviral Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Respiratory Antiviral Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Respiratory Antiviral Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Respiratory Antiviral Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Respiratory Antiviral Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. F. Hoffmann-La Roche Ltd. Company Details
Table 65. F. Hoffmann-La Roche Ltd. Business Overview
Table 66. F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Product
Table 67. F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 68. F. Hoffmann-La Roche Ltd. Recent Development
Table 69. Novartis AG Company Details
Table 70. Novartis AG Business Overview
Table 71. Novartis AG Respiratory Antiviral Treatment Product
Table 72. Novartis AG Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 73. Novartis AG Recent Development
Table 74. Takeda Pharmaceutical Company Limited Company Details
Table 75. Takeda Pharmaceutical Company Limited Business Overview
Table 76. Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Product
Table 77. Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 78. Takeda Pharmaceutical Company Limited Recent Development
Table 79. Pfizer, Inc. Company Details
Table 80. Pfizer, Inc. Business Overview
Table 81. Pfizer, Inc. Respiratory Antiviral Treatment Product
Table 82. Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 83. Pfizer, Inc. Recent Development
Table 84. Teva Pharmaceutical Industries Ltd. Company Details
Table 85. Teva Pharmaceutical Industries Ltd. Business Overview
Table 86. Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 87. Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Ltd. Recent Development
Table 89. Sun Pharmaceutical Industries Ltd. Company Details
Table 90. Sun Pharmaceutical Industries Ltd. Business Overview
Table 91. Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 92. Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 93. Sun Pharmaceutical Industries Ltd. Recent Development
Table 94. GlaxoSmithKline plc Company Details
Table 95. GlaxoSmithKline plc Business Overview
Table 96. GlaxoSmithKline plc Respiratory Antiviral Treatment Product
Table 97. GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 98. GlaxoSmithKline plc Recent Development
Table 99. Mylan Inc. Company Details
Table 100. Mylan Inc. Business Overview
Table 101. Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 102. Mylan Inc. Recent Development
Table 103. Merck & Co., Inc. Company Details
Table 104. Merck & Co., Inc. Business Overview
Table 105. Merck & Co., Inc. Respiratory Antiviral Treatment Product
Table 106. Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 107. Merck & Co., Inc. Recent Development
Table 108. AstraZeneca plc. Company Details
Table 109. AstraZeneca plc. Business Overview
Table 110. AstraZeneca plc. Respiratory Antiviral Treatment Product
Table 111. AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2016-2021) & (US$ Million)
Table 112. AstraZeneca plc. Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Respiratory Antiviral Treatment Market Share by Type: 2020 VS 2027
Figure 2. Influenza Features
Figure 3. Bronchiolitis Features
Figure 4. Pneumonia Features
Figure 5. Upper Respiratory Tract Infections (URTIs) Features
Figure 6. Others Features
Figure 7. Global Respiratory Antiviral Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Respiratory Antiviral Treatment Report Years Considered
Figure 12. Global Respiratory Antiviral Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Respiratory Antiviral Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Respiratory Antiviral Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Respiratory Antiviral Treatment Market Share by Regions (2022-2027)
Figure 16. Global Respiratory Antiviral Treatment Market Share by Players in 2020
Figure 17. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Respiratory Antiviral Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Respiratory Antiviral Treatment Revenue in 2020
Figure 19. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Respiratory Antiviral Treatment Market Share by Type (2016-2027)
Figure 23. North America Respiratory Antiviral Treatment Market Share by Application (2016-2027)
Figure 24. North America Respiratory Antiviral Treatment Market Share by Country (2016-2027)
Figure 25. United States Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Respiratory Antiviral Treatment Market Share by Type (2016-2027)
Figure 29. Europe Respiratory Antiviral Treatment Market Share by Application (2016-2027)
Figure 30. Europe Respiratory Antiviral Treatment Market Share by Country (2016-2027)
Figure 31. Germany Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Respiratory Antiviral Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Respiratory Antiviral Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Respiratory Antiviral Treatment Market Share by Region (2016-2027)
Figure 41. China Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Respiratory Antiviral Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Respiratory Antiviral Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Respiratory Antiviral Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Respiratory Antiviral Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Respiratory Antiviral Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Respiratory Antiviral Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Respiratory Antiviral Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 61. Novartis AG Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 62. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 63. Pfizer, Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 64. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 65. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 66. GlaxoSmithKline plc Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 67. Mylan Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 68. Merck & Co., Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 69. AstraZeneca plc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---